124 related articles for article (PubMed ID: 38836187)
21. Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review.
Song Z; Ren G; Wang X; Du H; Sun Y; Hu L
Ann Palliat Med; 2022 Mar; 11(3):1126-1134. PubMed ID: 35365043
[TBL] [Abstract][Full Text] [Related]
22. Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring
Chen CH; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE
Anticancer Res; 2022 Apr; 42(4):2145-2157. PubMed ID: 35347039
[TBL] [Abstract][Full Text] [Related]
23. Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients.
Tang YJ; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291877
[TBL] [Abstract][Full Text] [Related]
24. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
[TBL] [Abstract][Full Text] [Related]
25. Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib.
Ishii H; Azuma K; Sakai K; Naito Y; Matsuo N; Tokito T; Yamada K; Hoshino T; Nishio K
Sci Rep; 2020 Jan; 10(1):691. PubMed ID: 31959859
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of afatinib in an NSCLC patient with
Nozaki K; Watanabe S; Nishio K; Sakai K; Kikuchi T
Transl Cancer Res; 2022 Jan; 11(1):295-298. PubMed ID: 35261905
[TBL] [Abstract][Full Text] [Related]
27. On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation.
Brown BP; Zhang YK; Westover D; Yan Y; Qiao H; Huang V; Du Z; Smith JA; Ross JS; Miller VA; Ali S; Bazhenova L; Schrock AB; Meiler J; Lovly CM
Clin Cancer Res; 2019 Jun; 25(11):3341-3351. PubMed ID: 30796031
[TBL] [Abstract][Full Text] [Related]
28. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
29. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
[TBL] [Abstract][Full Text] [Related]
30. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R
Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885
[TBL] [Abstract][Full Text] [Related]
31. Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib.
Yamamoto N; Mera T; Märten A; Hochmair MJ
Adv Ther; 2020 Feb; 37(2):759-769. PubMed ID: 31863283
[TBL] [Abstract][Full Text] [Related]
32. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
33. Successful Treatment of Afatinib Reversing Epidermal Growth Factor Receptor Exon19Deletion/G724S Mutation Resistance Guided by Protein-Drug Docking.
Yu N; Xu Y; Wang X; Sun C; Qiu S; Guo Y; Bai M; Huang Y; Ma K
Oncologist; 2021 Nov; 26(11):e1903-e1908. PubMed ID: 34396638
[TBL] [Abstract][Full Text] [Related]
34. Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation.
Shen G; Shi L; Tian X; Huang D; Chen H; Gao C; Shen X; Zhang H
Front Pharmacol; 2021; 12():731895. PubMed ID: 34987382
[TBL] [Abstract][Full Text] [Related]
35. Rechallenge of afatinib for
Araki T; Kanda S; Komatsu M; Sonehara K; Tateishi K; Takada M; Kato A; Yamamoto M; Nishie K; Hama M; Agatsuma T; Kakizaki Y; Yoshiike F; Matsuo A; Chiaki T; Samizo K; Takagi Y; Yamaura M; Hanaoka M; Koizumi T
Transl Lung Cancer Res; 2023 Jun; 12(6):1320-1327. PubMed ID: 37425417
[TBL] [Abstract][Full Text] [Related]
36. Sequential Afatinib and Osimertinib in Asian Patients with
Miura S; Jung HA; Lee SY; Lee SH; Lee MK; Lee YC; Hochmair MJ; Yang CT; Märten A; Yang JC; Popat S
Onco Targets Ther; 2022; 15():873-882. PubMed ID: 36033903
[TBL] [Abstract][Full Text] [Related]
37. Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
Liu Y; Li Y; Ou Q; Wu X; Wang X; Shao YW; Ying J
Lung Cancer; 2018 Apr; 118():1-5. PubMed ID: 29571986
[TBL] [Abstract][Full Text] [Related]
38. Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro.
Nishino M; Suda K; Kobayashi Y; Ohara S; Fujino T; Koga T; Chiba M; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
Lung Cancer; 2018 Dec; 126():149-155. PubMed ID: 30527179
[TBL] [Abstract][Full Text] [Related]
39. Osimertinib
Gilardone S; Thapa R; Laborde J; Shafique M; Saltos A; Creelan B; Tanvetyanon T; Chiappori A; Simon G; Haura EB; Gray JE; Chen DT; Melzer D; Pellini B
J Thorac Dis; 2023 Nov; 15(11):6115-6125. PubMed ID: 38090314
[TBL] [Abstract][Full Text] [Related]
40. Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.
Kraskowski O; Stratmann JA; Wiesweg M; Eberhardt W; Metzenmacher M; Schmid KW; Herold T; Schildhaus HU; Darwiche K; Aigner C; Stuschke M; Laue K; Zaun G; Kasper S; Hense J; Sebastian M; Schuler M; Pogorzelski M
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9243-9252. PubMed ID: 37198447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
